213 related articles for article (PubMed ID: 25272055)
1. Converting potent indeno[1,2-b]indole inhibitors of protein kinase CK2 into selective inhibitors of the breast cancer resistance protein ABCG2.
Jabor Gozzi G; Bouaziz Z; Winter E; Daflon-Yunes N; Aichele D; Nacereddine A; Marminon C; Valdameri G; Zeinyeh W; Bollacke A; Guillon J; Lacoudre A; Pinaud N; Cadena SM; Jose J; Le Borgne M; Di Pietro A
J Med Chem; 2015 Jan; 58(1):265-77. PubMed ID: 25272055
[TBL] [Abstract][Full Text] [Related]
2. Phenolic indeno[1,2-b]indoles as ABCG2-selective potent and non-toxic inhibitors stimulating basal ATPase activity.
Gozzi GJ; Bouaziz Z; Winter E; Daflon-Yunes N; Honorat M; Guragossian N; Marminon C; Valdameri G; Bollacke A; Guillon J; Pinaud N; Marchivie M; Cadena SM; Jose J; Le Borgne M; Di Pietro A
Drug Des Devel Ther; 2015; 9():3481-95. PubMed ID: 26170632
[TBL] [Abstract][Full Text] [Related]
3. Substituted chromones as highly potent nontoxic inhibitors, specific for the breast cancer resistance protein.
Valdameri G; Genoux-Bastide E; Peres B; Gauthier C; Guitton J; Terreux R; Winnischofer SM; Rocha ME; Boumendjel A; Di Pietro A
J Med Chem; 2012 Jan; 55(2):966-70. PubMed ID: 22165858
[TBL] [Abstract][Full Text] [Related]
4. Indeno[1,2-b]indole derivatives as a novel class of potent human protein kinase CK2 inhibitors.
Hundsdörfer C; Hemmerling HJ; Götz C; Totzke F; Bednarski P; Le Borgne M; Jose J
Bioorg Med Chem; 2012 Apr; 20(7):2282-9. PubMed ID: 22377675
[TBL] [Abstract][Full Text] [Related]
5. Dimethoxyaurones: Potent inhibitors of ABCG2 (breast cancer resistance protein).
Sim HM; Lee CY; Ee PL; Go ML
Eur J Pharm Sci; 2008 Nov; 35(4):293-306. PubMed ID: 18725288
[TBL] [Abstract][Full Text] [Related]
6. Methoxy stilbenes as potent, specific, untransported, and noncytotoxic inhibitors of breast cancer resistance protein.
Valdameri G; Pereira Rangel L; Spatafora C; Guitton J; Gauthier C; Arnaud O; Ferreira-Pereira A; Falson P; Winnischofer SM; Rocha ME; Tringali C; Di Pietro A
ACS Chem Biol; 2012 Feb; 7(2):322-30. PubMed ID: 22039929
[TBL] [Abstract][Full Text] [Related]
7. Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2.
Dai CL; Liang YJ; Wang YS; Tiwari AK; Yan YY; Wang F; Chen ZS; Tong XZ; Fu LW
Cancer Lett; 2009 Jun; 279(1):74-83. PubMed ID: 19232821
[TBL] [Abstract][Full Text] [Related]
8. QSAR Model of Indeno[1,2-
Haidar S; Marminon C; Aichele D; Nacereddine A; Zeinyeh W; Bouzina A; Berredjem M; Ettouati L; Bouaziz Z; Le Borgne M; Jose J
Molecules; 2019 Dec; 25(1):. PubMed ID: 31888043
[TBL] [Abstract][Full Text] [Related]
9. Mechanistic basis of breast cancer resistance protein inhibition by new indeno[1,2-b]indoles.
Kita DH; Guragossian N; Zattoni IF; Moure VR; Rego FGM; Lusvarghi S; Moulenat T; Belhani B; Picheth G; Bouacida S; Bouaziz Z; Marminon C; Berredjem M; Jose J; Gonçalves MB; Ambudkar SV; Valdameri G; Le Borgne M
Sci Rep; 2021 Jan; 11(1):1788. PubMed ID: 33469044
[TBL] [Abstract][Full Text] [Related]
10. Symmetric bis-chalcones as a new type of breast cancer resistance protein inhibitors with a mechanism different from that of chromones.
Winter E; Devantier Neuenfeldt P; Chiaradia-Delatorre LD; Gauthier C; Yunes RA; Nunes RJ; Creczynski-Pasa TB; Di Pietro A
J Med Chem; 2014 Apr; 57(7):2930-41. PubMed ID: 24611893
[TBL] [Abstract][Full Text] [Related]
11. Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo.
Hu J; Zhang X; Wang F; Wang X; Yang K; Xu M; To KK; Li Q; Fu L
Oncotarget; 2015 Dec; 6(42):44643-59. PubMed ID: 26556876
[TBL] [Abstract][Full Text] [Related]
12. Diversity-oriented synthesis of pyrazolo[4,3-b]indoles by gold-catalysed three-component annulation: application to the development of a new class of CK2 inhibitors.
Hou Z; Oishi S; Suzuki Y; Kure T; Nakanishi I; Hirasawa A; Tsujimoto G; Ohno H; Fujii N
Org Biomol Chem; 2013 May; 11(20):3288-96. PubMed ID: 23535832
[TBL] [Abstract][Full Text] [Related]
13. Elacridar enhances the cytotoxic effects of sunitinib and prevents multidrug resistance in renal carcinoma cells.
Sato H; Siddig S; Uzu M; Suzuki S; Nomura Y; Kashiba T; Gushimiyagi K; Sekine Y; Uehara T; Arano Y; Yamaura K; Ueno K
Eur J Pharmacol; 2015 Jan; 746():258-66. PubMed ID: 25455500
[TBL] [Abstract][Full Text] [Related]
14. Investigation of chalcones as selective inhibitors of the breast cancer resistance protein: critical role of methoxylation in both inhibition potency and cytotoxicity.
Valdameri G; Gauthier C; Terreux R; Kachadourian R; Day BJ; Winnischofer SM; Rocha ME; Frachet V; Ronot X; Di Pietro A; Boumendjel A
J Med Chem; 2012 Apr; 55(7):3193-200. PubMed ID: 22449016
[TBL] [Abstract][Full Text] [Related]
15. The role of breast cancer resistance protein in acute lymphoblastic leukemia.
Plasschaert SL; van der Kolk DM; de Bont ES; Kamps WA; Morisaki K; Bates SE; Scheffer GL; Scheper RJ; Vellenga E; de Vries EG
Clin Cancer Res; 2003 Nov; 9(14):5171-7. PubMed ID: 14613996
[TBL] [Abstract][Full Text] [Related]
16. Discovery of alkoxyl biphenyl derivatives bearing dibenzo[c,e]azepine scaffold as potential dual inhibitors of P-glycoprotein and breast cancer resistance protein.
Gu X; Tang X; Zhao Q; Peng H; Peng S; Zhang Y
Bioorg Med Chem Lett; 2014 Aug; 24(15):3419-21. PubMed ID: 24928398
[TBL] [Abstract][Full Text] [Related]
17. Unexpected Binding Mode of a Potent Indeno[1,2-b]indole-Type Inhibitor of Protein Kinase CK2 Revealed by Complex Structures with the Catalytic Subunit CK2α and Its Paralog CK2α'.
Hochscherf J; Lindenblatt D; Witulski B; Birus R; Aichele D; Marminon C; Bouaziz Z; Le Borgne M; Jose J; Niefind K
Pharmaceuticals (Basel); 2017 Dec; 10(4):. PubMed ID: 29236079
[TBL] [Abstract][Full Text] [Related]
18. Investigation of quinazolines as inhibitors of breast cancer resistance protein (ABCG2).
Juvale K; Gallus J; Wiese M
Bioorg Med Chem; 2013 Dec; 21(24):7858-73. PubMed ID: 24184213
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells.
Robey RW; Medina-Pérez WY; Nishiyama K; Lahusen T; Miyake K; Litman T; Senderowicz AM; Ross DD; Bates SE
Clin Cancer Res; 2001 Jan; 7(1):145-52. PubMed ID: 11205902
[TBL] [Abstract][Full Text] [Related]
20. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
Nakamura Y; Oka M; Soda H; Shiozawa K; Yoshikawa M; Itoh A; Ikegami Y; Tsurutani J; Nakatomi K; Kitazaki T; Doi S; Yoshida H; Kohno S
Cancer Res; 2005 Feb; 65(4):1541-6. PubMed ID: 15735043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
